Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
SI-BONE, Inc. is a publicly traded medical device company focused on developing and commercializing minimally invasive surgical solutions for the treatment of disorders of the sacroiliac (SI) joint. The company operates within the orthopedic and spine medical device industry, with a primary emphasis on addressing chronic low back pain attributed to SI joint dysfunction, a condition historically underdiagnosed and undertreated.
The company’s core revenue driver is its proprietary iFuse Implant System®, which is designed to stabilize and fuse the SI joint using a minimally invasive approach. SI-BONE primarily serves orthopedic surgeons, neurosurgeons, and spine surgeons, with procedures reimbursed largely through established hospital and outpatient care pathways. Founded in 2008, the company was among the first to focus exclusively on SI joint fusion, positioning itself as a category pioneer with extensive clinical evidence supporting its products. SI-BONE completed its initial public offering in 2018 and has since focused on expanding clinical adoption and procedural awareness.
Business Operations
SI-BONE operates as a single-reportable-segment company focused on the development, manufacturing, and commercialization of SI joint treatment solutions. Its principal product portfolio includes the iFuse Implant System®, iFuse-TORQ®, and iFuse Bedrock Granite®, which are used in both lateral and posterior SI joint fusion procedures. Revenue is generated primarily through direct sales to hospitals and ambulatory surgery centers, supported by a specialized sales force and surgeon education programs.
The company conducts the majority of its commercial operations in the United States, with a smaller but growing international presence through a combination of direct sales and distributors. SI-BONE controls its core implant designs and clinical data assets, which are supported by multiple prospective clinical trials and long-term outcome studies. Public disclosures indicate no material joint ventures; available public sources show limited use of wholly owned subsidiaries, with operations largely integrated under the parent company.
Strategic Position & Investments
SI-BONE’s strategy centers on expanding the adoption of minimally invasive SI joint fusion by increasing surgeon training, strengthening clinical evidence, and broadening product indications. Growth initiatives include expanding posterior SI joint fusion offerings, driving increased utilization in outpatient and ambulatory surgical settings, and improving reimbursement coverage through payer engagement.
The company has historically emphasized internal research and development over large-scale acquisitions. Public filings indicate that growth has primarily been organic, supported by continued investment in clinical trials, post-market studies, and product line extensions. SI-BONE is also involved in advancing procedural techniques and instrumentation related to SI joint fusion; however, public disclosures do not indicate material investments in unrelated emerging technologies or diversified healthcare sectors.
Geographic Footprint
SI-BONE is headquartered in Santa Clara, California, and generates the substantial majority of its revenue from the United States. Its U.S. presence includes direct sales, clinical education, and surgeon support infrastructure across major metropolitan regions.
Internationally, the company has commercial activity in Europe, Canada, and select markets in the Asia-Pacific region, primarily through distributors and limited direct operations. While international revenue represents a smaller portion of total sales, the company has identified international expansion as a longer-term growth opportunity, subject to regulatory approvals and reimbursement dynamics in each region.
Leadership & Governance
SI-BONE was founded by Patrick J. Miles, who played a key role in establishing the company’s early focus on SI joint fusion as a distinct clinical category. The current leadership team emphasizes evidence-based adoption, surgeon education, and disciplined growth supported by clinical data and payer alignment.
Key executives include:
- Jeffrey A. Dunn – President and Chief Executive Officer
- Laura Francis – Chief Financial Officer
- Mark L. Capestro – Chief Commercial Officer
- Steven C. Hunter – Chief Operating Officer
- Keith R. Valentine – Chief Medical Officer
The leadership team’s strategic vision, as reflected in public filings and investor communications, centers on long-term market development, clinical validation, and operational scalability within the orthopedic and spine surgery markets.